Given the expected increase in the prevalence of double diabetes associated with overweight/obesity [61], the use of the highly effective weight loss medications semaglutide and tirzepatide (second-generation incretin analogs) in patients with T1D and LADA may keep on rising in the near future. This evidence concerns the gene GCG and obesity disorder.